Lasa Supergenerics
LASA NSE
Lasa Supergenerics
HealthcareNSE: LASA BSE: 540702 Pharmaceuticals & Biotechnology
Key Fundamentals
Volatility
Moderate
P/E Ratio
0
EBITDA
₹-28.40 Cr
Return on Equity
0%
Debt to Equity
0.12
Book Value
₹0
52W High
₹14.08
52W Low
₹5.67
Tapetide Score
Data-driven rating, 0–100. How it works →
Key Insights
Strengths
1- Stock is trading at 0.66 times its book value
Weaknesses
3- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of -34.0% over past five years.
- Company has a low return on equity of -9.95% over last 3 years.
Growth Rate
Revenue Growth
-82.96% lower than
3Y
Net Income Growth
134% higher than
3Y
Cash Flow Change
-232% lower than
3Y
ROE
-21.57% higher than
3Y
ROCE
17.46% higher than
3Y
EBITDA Margin (Avg.)
—
Quarterly Results
| Particulars | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 30.56 | 24.3 | 26.66 | 22.82 | 30.84 | 39.39 | 33.08 | 39.14 | 20.01 | 3.06 | 2.2 | -0.13 | 1.23 |
| Expenses | 26.51 | 23.25 | 25.6 | 26.81 | 29.04 | 38.6 | 32.81 | 35.73 | 20.51 | 7.06 | 2.95 | 1.99 | 2.62 |
| Operating Profit | 4.05 | 1.05 | 1.06 | -3.99 | 1.8 | 0.79 | 0.27 | 3.41 | -0.5 | -4 | -0.75 | -2.12 | -1.39 |
| OPM % | 13.25% | 4.32% | 3.98% | -17.48% | 5.84% | 2.01% | 0.82% | 8.71% | -2.5% | -130.72% | -34.09% | — | -113.01% |
| Other Income | 0 | 0.08 | 0 | -8.76 | 0 | 1.95 | 8.91 | -21.52 | -20.44 | 0.01 | 0.02 | -0.42 | -0.38 |
| Interest | 0.37 | 0.56 | 0.44 | 0.56 | 0.87 | 1.24 | 0.47 | 0.11 | 0.03 | 0.12 | 0.11 | 0.13 | 0.14 |
| Depreciation | 2.65 | 2.68 | 2.68 | 2.66 | 2.79 | 2.81 | 2.8 | 3.9 | 1.57 | 1.57 | 1.57 | 1.31 | 1.57 |
| PBT | 1.03 | -2.11 | -2.06 | -15.97 | -1.86 | -1.31 | 5.91 | -22.12 | -22.54 | -5.68 | -2.41 | -3.98 | -3.48 |
| Tax % | 580.58% | -99.05% | -29.61% | -4.2% | 46.77% | 146.56% | 7.11% | -35.4% | -6.3% | 10.04% | 5.81% | 4.77% | 3.16% |
| Net Profit | -4.95 | -0.02 | -1.46 | -15.3 | -2.73 | -3.23 | 5.49 | -14.29 | -21.12 | -6.25 | -2.55 | -4.16 | -3.58 |
| EPS in Rs | -0.99 | 0 | -0.29 | -3.05 | -0.54 | -0.64 | 1.1 | -2.85 | -4.22 | -1.25 | -0.51 | -0.83 | -0.71 |
Profit & Loss
| Particulars | Mar 2016 1m | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0 | 199 | 244 | 170 | 167 | 201 | 137 | 130 | 104 | 142 | 25 | 6 |
| Expenses | 0 | 153 | 202 | 158 | 137 | 154 | 120 | 136 | 102 | 136 | 32 | 15 |
| Operating Profit | 0 | 46 | 41 | 11 | 30 | 47 | 16 | -6 | 2 | 6 | -7 | -8 |
| OPM % | — | 23% | 17% | 7% | 18% | 24% | 12% | -4.9% | 2.1% | 4.4% | -29% | -130% |
| Other Income | 0 | -24 | 3 | 0 | 0 | 0 | -8 | -18 | -9 | -11 | -21 | -1 |
| Interest | 0 | 12 | 11 | 8 | 8 | 2 | 0 | 4 | 2 | 3 | 0 | 0 |
| Depreciation | 0 | 8 | 18 | 19 | 17 | 16 | 15 | 13 | 11 | 12 | 6 | 6 |
| PBT | 0 | 2 | 15 | -16 | 5 | 30 | -6 | -42 | -19 | -19 | -35 | -16 |
| Tax % | — | -10% | 19% | -25% | 23% | 23% | -13% | -9% | 14% | -24% | -2% | — |
| Net Profit | 0 | 2 | 12 | -12 | 4 | 23 | -5 | -39 | -22 | -15 | -34 | -17 |
| EPS in Rs | — | — | 5.4 | -5.26 | 0.89 | 5.6 | -1.31 | -7.71 | -4.34 | -2.95 | -6.8 | -3.3 |
| Div. Payout % | — | 0% | 0% | 0% | 0% | 4% | -24% | 0% | 0% | 0% | 0% | — |
Balance Sheet
| Particulars | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0.05 | 0.05 | 23 | 23 | 41 | 41 | 50 | 50 | 50 | 50 | 50 |
| Reserves | 0 | 75 | 94 | 82 | 101 | 118 | 108 | 68 | 47 | 34 | 0 |
| Borrowings | 0 | 116 | 107 | 85 | 48 | 19 | 20 | 22 | 22 | 2 | 10 |
| Other Liabilities | 0 | 37 | 63 | 69 | 42 | 29 | 31 | 24 | 32 | 16 | 7 |
| Total Liabilities | 0 | 228 | 287 | 258 | 232 | 208 | 209 | 164 | 151 | 102 | 66 |
| Fixed Assets | 0 | 119 | 170 | 162 | 152 | 143 | 137 | 119 | 110 | 68 | 55 |
| CWIP | 0 | 30 | 7 | 7 | 0 | 0 | 5 | 5 | 3 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 0 | 80 | 110 | 90 | 80 | 65 | 67 | 40 | 39 | 33 | 11 |
| Total Assets | 0 | 228 | 287 | 258 | 232 | 208 | 209 | 164 | 151 | 102 | 66 |
Cash Flow
| Particulars | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | 0 | -3 | 40 | 41 | 14 | 41 | 9 | -17 | 2 | -3 | 0 |
| Investing | 0 | 0 | -44 | -7 | -2 | -4 | -3 | 11 | 0 | 8 | 0 |
| Financing | 0 | 0 | 4 | -33 | -10 | -36 | 0 | -4 | -2 | -6 | 0 |
| Net Cash Flow | 0 | -3 | 0 | 0 | 2 | 1 | 6 | -10 | 0 | 0 | 0 |
| Free Cash Flow | 0 | -5 | -6 | 29 | 13 | 35 | 12 | -12 | 0 | 5 | 0 |
| CFO/OP | — | -6 | 103 | 397 | 46 | 87 | 73 | 273 | 96 | -45 | 1 |
Ratios
| Particulars | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | — | 64 | 63 | 62 | 45 | 27 | 50 | 7 | 13 | 4 | 1 |
| Inventory Days | — | 93 | 90 | 90 | 101 | 56 | 46 | 48 | 92 | 84 | 28 |
| Days Payable | — | 71 | 102 | 170 | 130 | 41 | 68 | 32 | 68 | 35 | 32 |
| Cash Conversion Cycle | — | 87 | 51 | -18 | 16 | 42 | 28 | 22 | 37 | 53 | -4 |
| Working Capital Days | — | 15 | -1 | -52 | -13 | 35 | 12 | -17 | -44 | 37 | -102 |
| ROCE % | — | 42% | 13% | -4% | 7% | 17% | 1% | -12% | -6% | -1% | -18% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Lasa Supergenerics insights
65 extracted metrics + investor summaries across FY16–FY26.
Documents
1
Declaration With Respect To Non -Applicability Of Large Entities
16 Apr - Company declares it is not a Large Corporate under SEBI debt-fundraising framework. 16 Apr - Company declares it is not a Large Corporate under SEBI debt-fundraising framework.
2
Closure of Trading Window
30 Mar - Trading window closed Apr 1, 2026 until 48 hours after audited results for quarter/year ended Mar 31, 2026. 30 Mar - Trading window closed Apr 1, 2026 until 48 hours after audited results for quarter/year ended Mar 31, 2026.
3
Board Meeting Outcome for Outcome Of Board Meeting For Quarter Ended 31St December , 2025
13 Feb - Approved Q2 results; 18 May 2025 fire caused Rs20.57 crore uninsured loss; operations halted. 13 Feb - Approved Q2 results; 18 May 2025 fire caused Rs20.57 crore uninsured loss; operations halted.
5
Integrated Filing For Quarter Ended December 31, 2025
13 Feb - May 18, 2025 fire: uninsured losses Rs 2,057.47 lakhs; operations halted; Q3 results approved. 13 Feb - May 18, 2025 fire: uninsured losses Rs 2,057.47 lakhs; operations halted; Q3 results approved.
Frequently Asked Questions about Lasa Supergenerics
What does Lasa Supergenerics Ltd do?
Incorporated in 2016, Lasa Supergenerics Ltd is in the business of manufacturing, trading, producing, processing, preparing, treating chemicals, API, Pharmaceuticals, drugs, etc.[1]
Where is Lasa Supergenerics Ltd (LASA) listed?
Lasa Supergenerics Ltd trades as LASA on the NSE and under code 540702 on the BSE.
Which sector does Lasa Supergenerics Ltd belong to?
Lasa Supergenerics Ltd is classified under the Healthcare sector, in the Pharmaceuticals & Biotechnology industry.
What is the PE ratio of Lasa Supergenerics Ltd?
Lasa Supergenerics Ltd trades at a PE ratio of 0.00, against a book value of ₹0 per share.
What is the 52-week high and low of Lasa Supergenerics Ltd?
Over the last 52 weeks Lasa Supergenerics Ltd has traded between ₹5.67 and ₹14.08.
Does Lasa Supergenerics Ltd pay dividends?
Lasa Supergenerics Ltd has a dividend yield of 3.83%.
What is the Return on Equity (ROE) of Lasa Supergenerics Ltd?
Lasa Supergenerics Ltd reported a return on equity of 0.00%. Its debt-to-equity ratio is 0.12.
Company Information
Incorporated in 2016, Lasa Supergenerics Ltd is in the business of manufacturing, trading, producing, processing, preparing, treating chemicals, API, Pharmaceuticals, drugs, etc.[1]
Website lasalabs.com
CEO Dr. Omkar Pravin Herlekar
Employees 66
Listed 2017-09-21
Face Value ₹ 10
Issued Size 5,01,01,239
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/LASA.md for Lasa Supergenerics Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live,
structured queries instead of documents, use our MCP server.